Issued on behalf of Conexeu Sciences Inc.

A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization -- in one of medicine's most consequential frontiers.

RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary -- There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then -- in the critical window right after listing -- races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 15, 2026, Conexeu Sciences Inc. (Nasdaq: CNXU), a preclinical-stage regenerative-tissue company that began trading only weeks earlier, offered a revealing answer: it expanded its board from six to nine directors, promoted a co-founder to Chief Commercial Officer, and added a prominent aesthetics-industry figure to its advisory board -- five appointments in all, weighted heavily toward Fortune 500 finance, capital-markets, and commercialization experience.

The move is less about any single hire than about what the collective résumé signals. For a company whose lead technology is still preclinical, building a board stocked with big-company financial and operating discipline is a statement of intent: that Conexeu means to be judged not as a science project, but as a company on a path to commercialization in one of the most consequential frontiers in medicine -- helping the body regenerate its own tissue. Whether it can deliver on that intent remains years from resolution, but the governance build-out is the kind of step investors in early-stage medtech tend to watch closely.

Key Takeaways

   --  Board expanded from six to nine: Conexeu appointed Ana Bastiani-Posner, 
      April Burke, and Andrew Costa as new directors, deepening its bench 
      across healthcare finance, capital markets, M&A, and growth equity. 
 
   --  A commercialization signal: Co-founder and director David Bogart was 
      named Chief Commercial Officer to lead commercial strategy and operations, 
      having helped shape the company's platform and regulatory pathway from 
      inception. 
 
   --  An aesthetics heavyweight on advisory: Melinda Farina, known as "The 
      Beauty Broker" and founder of Integrated Aesthetics Consulting and Beauty 
      Brokers Inc., joined the advisory board, reinforcing Conexeu's push into 
      the aesthetics market. 
 
   --  Pedigree that stands out: The new directors bring senior roles from 
      Kyowa Kirin, Allergan, Novartis, Schering-Plough, Lucid Hearing, RX3 
      Growth Partners (the consumer growth-equity firm co-founded by NFL 
      quarterback Aaron Rodgers), Morgan Stanley, and J.P. Morgan. 
 
   --  Context -- momentum and risk: The appointments follow Conexeu's May 2026 
      Nasdaq listing and June bell-ringing, as it advances its preclinical 
      CXU$(TM)$ platform toward a targeted early-2027 FDA 510(k) submission -- a 
      milestone, not a guarantee. 

Who Conexeu Just Brought In

The headline additions are notable for their financial and operating heft. Ana Bastiani-Posner, named chair of the Compensation Committee and a member of the Audit Committee, is a C-suite executive with more than two decades of leadership across Fortune 500 companies; she currently serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, where she helps oversee roughly $1.2 billion in annual revenue, and has held senior roles at Allergan, the New York Genome Center, Schering-Plough, and Novartis. April Burke, joining the Audit and Compensation Committees, is Executive Vice President and CFO of Lucid Hearing, with expertise spanning public companies, private-equity-backed organizations, capital allocation, M&A, and IPO readiness.

Andrew Costa, named chair of the Audit Committee, rounds out the new directors as an investor and growth-equity operator with fifteen years across private equity, investment banking, and military leadership. He is Co-Managing Partner of RX3 Growth Partners -- the consumer-focused growth-equity firm co-founded by NFL quarterback Aaron Rodgers, investing in health, wellness, and active-lifestyle brands, where he sits on boards including Therabody -- and previously held investment-banking roles at Morgan Stanley and J.P. Morgan, after serving as a Captain in the U.S. Air Force. Alongside the board additions, co-founder and director David Bogart was elevated to Chief Commercial Officer; a capital-markets and investor-relations strategist who has advised on more than $75 million in capital formation, Bogart has helped shape Conexeu's IP and regulatory strategy since inception. And on the advisory side, Melinda Farina -- "The Beauty Broker," with nearly three decades in medical aesthetics -- brings consumer-health, brand-development, and market-positioning expertise directly relevant to Conexeu's aesthetics ambitions.

"Conexeu is entering an exciting new phase of growth, and it is important that our leadership team reflects the breadth of expertise needed to support both our scientific vision and business strategy," said Miles Harrison, CEO and President of Conexeu Sciences, adding that he looked forward to working with Bogart to "build our commercial foundation, expand our pipeline, and position Conexeu for scalable growth."

What the Company Is Actually Building

The leadership news only matters because of what sits beneath it. Conexeu is a preclinical-stage regenerative-tissue company built around a proprietary bioregenerative extracellular matrix platform it calls CXU(TM). The extracellular matrix is the natural scaffolding that surrounds cells in the body, providing the structural and biochemical cues that tell cells where to go and how to rebuild. Conexeu's lead device candidate, Ten-Minute Tissue(TM), is a thermosensitive ECM engineered to remain fluid at room temperature and then transition into a stable gel scaffold in place, at body temperature, within roughly ten minutes -- a property designed to let it conform to and fill the irregular, three-dimensional geometry of real wounds and soft-tissue defects that flat sheets and powders struggle to address.

The company frames its strategy with a deliberately simple refrain -- "one formula, one device" -- a single platform engineered to scale across multiple billion-dollar markets rather than the traditional one-molecule, one-indication model. Those target markets include advanced wound care, periodontal applications, and facial and body contouring (including the soft-tissue laxity associated with rapid GLP-1-driven weight loss), with longer-term expansion into 3D printing and biofabrication and even veterinary medicine. Conexeu has also unveiled a 3D-bioprinted regenerative breast matrix program, branded B.R.E.A.S.T.(TM), in preclinical development with the Wake Forest Institute for Regenerative Medicine, aimed at moving breast reconstruction beyond implants toward true tissue regeneration. The platform rests on more than a decade of university preclinical research and is protected by issued patents across the U.S., E.U., Japan, and Australia, with Conexeu holding full rights and no royalty obligations. Management is pursuing a predicate-based U.S. regulatory route, with a 510(k) submission for its initial wound-care indication targeted for early 2027.

A Sector With Powerful Tailwinds -- and Heavyweight Players

Conexeu is wading into a field with genuine momentum. The shift from simply replacing or covering damaged tissue toward actively regenerating it spans several large, growing markets -- advanced wound care, medical aesthetics and body contouring, and surgical reconstruction -- all propelled by aging populations, the diabetes epidemic, and, increasingly, the GLP-1 weight-loss wave and the soft-tissue changes that follow it. To understand both the scale of the opportunity and the competition, it helps to look at the established public companies operating across the markets Conexeu is targeting. They are far larger, commercial, and more diversified, which makes them useful reference points rather than direct equivalents.

Smith+Nephew plc $(SNN)$ is one of the clearest reference points for the wound-care and tissue-repair side of Conexeu's platform. A global medical-technology company explicitly focused on the repair, regeneration, and replacement of soft and hard tissue, Smith+Nephew operates a leading advanced wound management business and bioinductive regenerative implants. It illustrates the scale and breadth a tissue-technology franchise can reach -- and the entrenched, well-capitalized competition any newcomer in regenerative wound care must eventually reckon with.

AbbVie Inc. $(ABBV)$ anchors the aesthetics comparison through its Allergan Aesthetics division, the dominant force in medical aesthetics with a multibillion-dollar franchise spanning injectables and body contouring. AbbVie has been actively addressing the aesthetic consequences of GLP-1-driven weight loss -- precisely the soft-tissue laxity Conexeu is targeting -- making it a powerful illustration of how large the aesthetics opportunity is, and how formidable the incumbent is in the market Conexeu hopes to enter with a regenerative approach.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) is perhaps the most thematically precise comparison for Conexeu's breast program. A pure-play breast-aesthetics-and-reconstruction company built around its Motiva implants and tissue-expander technologies, Establishment Labs has grown into a company with more than $200 million in annual revenue. As Conexeu advances its B.R.E.A.S.T.(TM) bioprinted matrix toward a regenerative alternative to implant-based reconstruction, Establishment Labs represents both the established approach Conexeu aims to leapfrog and the commercial scale a focused breast-health franchise can achieve.

(MORE TO FOLLOW) Dow Jones Newswires

June 16, 2026 08:15 ET (12:15 GMT)